Table 6.

Clinical characteristics of patients with AAV and active severe renal disease according with the status of treatment with PLEX (n=251)

CharacteristicNo PLEX n=200 (79.7%)PLEX n=51 (20.3%)Std. Diff. (%)a
Age at diagnosis of severe renal involvement, median (IQR) yrb67 (55–75)65 (56–74)−3.5
Male, n (%)97 (48.5)31 (60.8)24.9
AAV, n (%)
 MPA120 (60.0)20 (39.2)−42.5
 GPA80 (40.0)31 (60.8)42.5
ANCA specificity (ELISA), n (%)
 MPO134 (67.0)22 (43.1)−49.5
 PR366 (33.0)29 (56.9)49.5
BVAS/WG at diagnosis, median (IQR)7 (7–10)9 (7–12)39.7
Renal limited disease at diagnosis, n (%)74 (37.0)10 (19.6)−39.3
Rapidly progressive GN, n (%)74 (37.0)23 (45.1)16.5
Alveolar hemorrhage BVAS/WG at diagnosis, n (%)25 (12.5)15 (29.4)42.4c
Biopsy proven, n (%)178 (89.0)44 (86.3)−8.2
Cardiovascular risk factors, n (%)
 Arterial hypertension151 (75.5)36 (70.6)−11.1
 Diabetes mellitus43 (21.5)13 (25.5)9.4
 Dyslipidemia71 (35.5)20 (39.2)7.7
 BMI>30 kg/m267 (36.0)20 (44.4)17.2
Laboratory findings
 Hemoglobin, mean (SD) g/dl9.9 (9.0–11.3)9.2 (7.9–10.0)−64.6
 ESR>22 mm/1st h, n (%)122 (81.9)23 (79.3)−6.6
 eGFR at diagnosis of renal involvement, mean (SD) ml/min per 1.73 m216.8 (7.0)14.1 (8.0)−36.0
 eGFR at diagnosis of renal involvement <15 ml/min per 1.73 m2, n (%)75 (37.5)29 (56.9)39.6c
 eGFR at 6 mo, median (IQR)29.9 (20.1–40.5)27.7 (14.2–43.0)−10.1
 eGFR at 12 mo, median (IQR)31.8 (21.2–42.0)30.6 (22.1–49.2)0.5
 eGFR at 18 mo, median (IQR)33.2 (21–6– 44.8)32.4 (19.2–43.8)−13.4
 eGFR at 24 mo, median (IQR)33.3 (22.2–45.0)32.6 (21.8–49.8)−4.1
Remission-induction immunosuppression, n (%)
 iv methylprednisolone111 (55.5)46 (90.2)84.7c
 CYC124 (62.0)37 (72.5)22.5c
 RTX50 (25.0)14 (27.5)5.7c
Maintenance treatment, n (%)
 Azathioprine62 (31.0)16 (31.4)0.9
 Mycophenolate mofetil50 (25.0)10 (19.6)−13.0
 RTX18 (9.0)10 (19.6)30.6
 CYC14 (7.0)2 (3.9)−13.7
 Prednisone56 (28.0)13 (25.5)−5.7
Prednisone dose, median (IQR) mg
 month 6 (122 versus 36)7.5 (0.0–15.0)5.0 (0.0–13.8)−16.9
 month 12 (94 versus 29)5.0 (0.0–10.0)5.0 (0.0–5.5)7.7
 month 18 (87 versus 24)0.0 (0.0–7.0)0.0 (0.0–5.0)−12.7
 month 24 (80 versus 23)0.0 (0.0–5.0)0.0 (0.0–5.0)−17.6
  • eGFR is estimated using the Chronic Kidney Disease Epidemiology collaboration method. IQR, interquartile range; GPA, granulomatosis with polyangiitis; ESR, erythrocyte sedimentation rate.

  • a Standardized mean differences.

  • b Treatment was started on average within 16 h of the diagnosis of severe renal involvement.

  • c Variables used in the propensity score.